EA202090757A1 - T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 - Google Patents

T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53

Info

Publication number
EA202090757A1
EA202090757A1 EA202090757A EA202090757A EA202090757A1 EA 202090757 A1 EA202090757 A1 EA 202090757A1 EA 202090757 A EA202090757 A EA 202090757A EA 202090757 A EA202090757 A EA 202090757A EA 202090757 A1 EA202090757 A1 EA 202090757A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mutant
cell receptors
mammal
disclosed
methods
Prior art date
Application number
EA202090757A
Other languages
English (en)
Inventor
Дрю С. Денигер
Стивен А. Розенберг
Анна Пасетто
Рами Йозеф
Уинифред М. Ло
Йон-Чэнь Лу
Мария Р. Паркхёрст
Пол Ф. Роббинс
Париза Малекзадех
Original Assignee
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез filed Critical Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез
Publication of EA202090757A1 publication Critical patent/EA202090757A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Раскрыт выделенный или очищенный T-клеточный рецептор (TCR), обладающий антигенной специфичностью в отношении мутантного человеческого p53. Также предложены родственные полипептиды и белки, а также родственные нуклеиновые кислоты, рекомбинантные экспрессионные векторы, клетки-хозяева, популяции клеток и фармацевтические композиции. Также раскрыты способы выявления наличия рака у млекопитающего и способы лечения или предупреждения рака у млекопитающего.
EA202090757A 2017-09-29 2018-09-17 T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 EA202090757A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29
PCT/US2018/051285 WO2019067243A1 (en) 2017-09-29 2018-09-17 T CELL RECEPTORS RECOGNIZING P53 MUTE

Publications (1)

Publication Number Publication Date
EA202090757A1 true EA202090757A1 (ru) 2020-08-21

Family

ID=63714167

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090757A EA202090757A1 (ru) 2017-09-29 2018-09-17 T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53

Country Status (15)

Country Link
US (1) US11939365B2 (ru)
EP (1) EP3688027A1 (ru)
JP (2) JP7324193B2 (ru)
KR (1) KR20200064110A (ru)
CN (1) CN111386282A (ru)
AU (1) AU2018342246A1 (ru)
BR (1) BR112020006012A2 (ru)
CA (1) CA3077024A1 (ru)
CR (1) CR20200170A (ru)
EA (1) EA202090757A1 (ru)
IL (1) IL273515A (ru)
MA (1) MA50651A (ru)
MX (1) MX2020003504A (ru)
SG (1) SG11202002636PA (ru)
WO (1) WO2019067243A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3551221T3 (pl) 2016-12-08 2022-02-28 Immatics Biotechnologies Gmbh Nowe receptory komórek t i immunoterapia z ich zastosowaniem
WO2020237368A1 (en) * 2019-05-27 2020-12-03 Provincial Health Services Authority Immunotherapy constructs targeting kras antigens
JP2022538148A (ja) * 2019-06-27 2022-08-31 アメリカ合衆国 ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
CA3191186A1 (en) * 2020-09-04 2022-03-10 Sanghyun Kim T cell receptors recognizing r273c or y220c mutations in p53
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
CN117957245A (zh) * 2021-05-07 2024-04-30 美国政府(由卫生和人类服务部的部长所代表) 识别p53中的c135y、r175h或m237i突变的t细胞受体
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) * 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
US7456263B2 (en) * 2001-06-05 2008-11-25 Altor Bioscience Corporation P53 binding T cell receptor molecules
EP1545204B1 (en) 2002-09-06 2016-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CA2920147C (en) * 2013-08-07 2022-09-20 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
MX369513B (es) * 2014-02-14 2019-11-11 Univ Texas Receptores de antígenos quiméricos y métodos de realización.
JP2017514471A (ja) * 2014-04-23 2017-06-08 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法
LT3149031T (lt) 2014-05-29 2020-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T ląstelių receptoriai prieš žmogaus papilomos virusą 16 e7
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
AU2014407540C1 (en) 2014-10-02 2021-07-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
EP3265079A4 (en) 2015-03-03 2019-01-02 Caris MPI, Inc. Molecular profiling for cancer
CA2984234C (en) * 2015-05-01 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)

Also Published As

Publication number Publication date
BR112020006012A2 (pt) 2020-10-06
JP7324193B2 (ja) 2023-08-09
KR20200064110A (ko) 2020-06-05
JP2023159112A (ja) 2023-10-31
SG11202002636PA (en) 2020-04-29
CR20200170A (es) 2020-11-23
US20200277352A1 (en) 2020-09-03
IL273515A (en) 2020-05-31
US11939365B2 (en) 2024-03-26
CA3077024A1 (en) 2019-04-04
CN111386282A (zh) 2020-07-07
EP3688027A1 (en) 2020-08-05
JP2021500010A (ja) 2021-01-07
WO2019067243A1 (en) 2019-04-04
MA50651A (fr) 2020-08-05
MX2020003504A (es) 2020-09-14
AU2018342246A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
EA202090652A1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
MX2019009641A (es) Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.
MX2017006865A (es) Receptores de células t de kras anti-mutado.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX2024001190A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
WO2019002444A9 (en) NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
FI3380115T3 (fi) Peptidejä piwil1:stä
EA202192726A1 (ru) Magea1-специфические т-клеточные рецепторы и их использование
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
BR112022006177A2 (pt) Kir3dl3 é um receptor inibidor do sistema imune e do mesmo
MX2018003445A (es) Expresion de proteinas que contienen fc.
WO2022051449A3 (en) T cell receptors recognizing r273c or y220c mutations in p53